X4 Pharmaceuticals
XFOR
79 hedge funds and large institutions have $358M invested in X4 Pharmaceuticals in 2025 Q4 according to their latest regulatory filings, with 42 funds opening new positions, 17 increasing their positions, 8 reducing their positions, and 4 closing their positions.
950% more first-time investments, than exits
New positions opened: 42 | Existing positions closed: 4
547% more capital invested
Capital invested by funds: $55.3M → $358M (+$302M)
300% more funds holding in top 10
Funds holding in top 10: 1 → 4 (+3)
113% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 8
88% more funds holding
Funds holding: 42 → 79 (+37)
30.3% more ownership
Funds ownership: 71.98% → 102.28% (+30%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$30.9M |
| 2 |
Morgan Stanley
New York
|
+$29.8M |
| 3 |
PA
Perceptive Advisors
New York
|
+$22.9M |
| 4 |
SVCM
Saturn V Capital Management
Austin,
Texas
|
+$21.1M |
| 5 |
BCLSI
Bain Capital Life Sciences Investors
Boston,
Massachusetts
|
+$20.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KCM
Kingdon Capital Management
New York
|
-$3.19M |
| 2 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$1.68M |
| 3 |
BFM
Boothbay Fund Management
New York
|
-$1.18M |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$566K |
| 5 |
Renaissance Technologies
New York
|
-$65.6K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
RWM
76
RMG Wealth Management
Platteville,
Wisconsin
| $64 | +$102 | +28 | New |
|
|
HWM
77
HighMark Wealth Management
St. Paul,
Minnesota
| $24 | – | – | – |
|
78
Northwestern Mutual Wealth Management
Milwaukee,
Wisconsin
| $20 | +$18 | +5 | New |
|
|
KCM
79
Kingdon Capital Management
New York
| – | -$3.19M | -933,332 | Closed |
|
|
BFM
80
Boothbay Fund Management
New York
| – | -$1.18M | -343,963 | Closed |
|
|
81
Renaissance Technologies
New York
| – | -$65.6K | -19,177 | Closed |
|
82
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$8.82K | -2,429 | -96% |
|
|
TWC
83
TD Waterhouse Canada
Toronto,
Ontario, Canada
| – | -$5.37K | -1,500 | Closed |
|
XFOR Hedge Fund Activity: Q4 2025 in Review
79 of the 8,223 institutional investors tracked by Wall St. Rank reported a position in X4 Pharmaceuticals (XFOR) for Q4 2025, worth a combined $358M — up 547% from $55.3M a quarter earlier.
Buyers outnumbered sellers: 42 funds opened new XFOR positions and 4 closed out — a net gain of 38 holders — while 17 added to existing stakes and 8 trimmed.
The largest buyer was Fidelity Investments, opening a new position worth an estimated $30.9M. The largest seller was Kingdon Capital Management, exiting entirely with an estimated $3.19M sold.
- 79 institutional investors held X4 Pharmaceuticals (XFOR) as of Q4 2025, up from 42 in Q3 2025.
- Funds reported $358M of X4 Pharmaceuticals stock for Q4 2025, up 547% quarter-over-quarter.
- 42 funds opened new X4 Pharmaceuticals positions in Q4 2025 and 4 closed out, a net change of +38 holders.
- The largest X4 Pharmaceuticals buyer in Q4 2025 was Fidelity Investments, an estimated $30.9M added.
- The largest X4 Pharmaceuticals seller in Q4 2025 was Kingdon Capital Management, an estimated $3.19M sold.
Based on aggregated 13F filings for Q4 2025.